Novo Nordisk acquiring Akero Therapeutics for $5.2bn
Denmark-based global pharma company Novo Nordisk is to acquire clinical stage company Akero Therapeutics for up to $5.2bn, filling a critical comorbidity gap within Novo Nordisk’s core therapeutic landscape. The deal adds potential first-in-class MASH (Metabolic Dysfunction-Associated Steatohepatitis, a severe form of fatty liver disease) therapy. This is Novo Nordisk’s largest R&D-focused acquisition to date, strategically aligning with its core…